secwatch.observer — SEC 8-K summary
======================================

Issuer:     ZEVRA THERAPEUTICS, INC. (ZVRA)
CIK:        0001434647
Form:       8-K
Filed at:   2026-03-16T23:59:59+00:00
Accession:  0001434647-26-000015
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 1.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zevra sells SDX portfolio to Commave for $50M, settles lawsuit, repays $63M debt
--------------------------------------------------------------------------------

- Total purchase price $50M; $25M at signing, $20M within 10 business days, $5M after records delivery.
- Litigation with Commave in Delaware Chancery dismissed with prejudice; both parties release all claims.
- Repaid $63M term loan (incl. $3M PIK interest) in full, terminating Credit Agreement and all liens.
- CEO Neil McFarlane highlights debt-free balance sheet and enhanced financial flexibility.
- Commave receives worldwide royalty-free perpetual license to SDX patents retained by Zevra.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434647/000143464726000015/0001434647-26-000015-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434647/000143464726000015/zvra-20260312.htm
  HTML page:      https://secwatch.observer/filing/0001434647-26-000015

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer